Stay updated with breaking news from Trda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Entrada Therapeutics (NASDAQ:TRDA – Get Rating) had its target price cut by equities research analysts at The Goldman Sachs Group from $22.00 to $10.00 in a report released on Tuesday, Stock Target Advisor reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside […] ....
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) major shareholder Bros. Advisors Lp Baker bought 19,000 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were bought at an average cost of $5.83 per share, for a total transaction of $110,770.00. Following the purchase, the insider now owns 4,374,493 shares of […] ....
Entrada Therapeutics (NASDAQ:TRDA – Get Rating) posted its quarterly earnings data on Tuesday. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.40, MarketWatch Earnings reports. Shares of TRDA stock opened at $8.98 on Wednesday. Entrada Therapeutics has a one year low of $7.24 and a one […] ....